← All trials
NCT02076191
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Feb 1, 2018
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- National Cancer Institute (NCI)Collaborator
- IncyteCollaborator
- Myeloproliferative Disorders Research ConsoritumCollaborator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Icahn School of Medicine at Mount SinaiStudy chair
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.